BGI in pact with Singapore's Clearbridge on biopsy tool

DNA
DNA

Shenzhen-based genomics powerhouse BGI will develop a liquid biopsy screening tool in China using technology developed by National University of Singapore spinoff Clearbridge BioMedics in a pact initially focused on potential personalized medicine applications in lung, breast and liver cancers.

The product developed by Clearbridge--ClearCell FX1--is used to separate circulating tumor cells from blood samples.

Under the terms of the agreement, BGI will draw upon its genomic expertise to develop further clinical and research applications in diagnostics. In particular, according to its release, the partners are looking at cancer-related targeted gene analysis, drug-related gene analysis, single cell analysis and cancer immunotherapy.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

"We believe that liquid biopsy plays a key role in clinical diagnostics and personalized medicine and can potentially even aid in immunotherapy PD-L1 treatment management," Johnson Chen, chairman and founder of Clearbridge BioMedics, said in the release.

BGI has reportedly mulled a mainland China initial public offering by the end of 2016--following management changes in the past year that appeared to lead to a slowdown in expansion plans.

BGI began in 1999 as Beijing Genomics Institute with the help of government institutions and has since bought Mountain View, CA-based Complete Genomics, where the halt of a population-scale sequencing platform late last year led to job cuts. It has also previously made a series of partnership moves aimed at big data service offerings in genomic research.

- here's the release

Read more on

Suggested Articles

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.

It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.